Amphastar Pharmaceuticals 

$27.92
281
+$1.43+5.4% Monday 21:00

統計

當日最高
28.13
當日最低
26.34
52週高點
34.39
52週低點
20.39
成交量
433,403
平均成交量
387,685
市值
1.28B
本益比
9.55
股息殖利率
-
股息
-

即將到來

財報

4Mar預期
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
下一步
0.69
0.79
0.89
0.99
預期EPS
0.925271
實際EPS
不適用

財務

21.79%利潤率
有盈利
2019
2020
2021
2022
2023
2024
1.46B營收
319.04M淨利

分析師評級

$30.25平均目標價
最高預估為 34.00。
來自過去6個月內的 4 則評分。這不是投資建議。
買入
25%
持有
75%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 AMPH 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Show more...
執行長
Dr. Ziping Luo Ph.D.
員工
2028
國家
US
ISIN
US03209R1032

上市

0 Comments

分享你的想法

FAQ

Amphastar Pharmaceuticals 今天的股價是多少?
AMPH 目前價格為 $27.92 USD,過去 24 小時上漲了 +5.4%。在圖表上更密切關注 Amphastar Pharmaceuticals 股價表現。
Amphastar Pharmaceuticals 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Amphastar Pharmaceuticals 的股票以代號 AMPH 進行交易。
Amphastar Pharmaceuticals 的股價在上漲嗎?
AMPH 股票較上週上漲 +6.36%,本月上漲 +5.52%,但過去一年 Amphastar Pharmaceuticals 下跌 -16.38%。
Amphastar Pharmaceuticals 的市值是多少?
今天 Amphastar Pharmaceuticals 的市值為 1.28B
Amphastar Pharmaceuticals 下一次財報日期是什麼時候?
Amphastar Pharmaceuticals 將於 March 04, 2026 公布下一次財報。
Amphastar Pharmaceuticals 上一季度的財報如何?
AMPH 上一季度的財報為每股 0.93 USD,預估為 0.83 USD,帶來 +12.68% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Amphastar Pharmaceuticals 去年的營收是多少?
Amphastar Pharmaceuticals 去年的營收為 1.46BUSD。
Amphastar Pharmaceuticals 去年的淨利是多少?
AMPH 去年的淨收益為 319.04MUSD。
Amphastar Pharmaceuticals 有多少名員工?
截至 February 03, 2026,公司共有 2,028 名員工。
Amphastar Pharmaceuticals 位於哪個產業?
Amphastar Pharmaceuticals從事於Health Care產業。
Amphastar Pharmaceuticals 何時完成拆股?
Amphastar Pharmaceuticals 最近沒有進行任何拆股。
Amphastar Pharmaceuticals 的總部在哪裡?
Amphastar Pharmaceuticals 的總部位於 US 的 Rancho Cucamonga。